XORTX Therapeutics Inc. is a biotechnology company with four drug development programs: One of these programs is at the pre-NDA filing stage – XRx-026 for gout; two are clinically advanced products under development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and XRx-101 for Coronavirus / COVID-19 infection. XRx-225 focuses on Type 2 Diabetic Nephropathy (T2DN). XORTX is working towards an NDA filing for its gout drug in the near future, as well as advancing its clinical development-stage products – XRx-008 and XRx-101 - all of which target xanthine oxidase to inhibit the production of uric acid in patients. The Company has a growing portfolio of intellectual property.
XORTX’s pipeline includes proprietary and novel product candidates currently in clinical development:
XRx-026 is in the final stages of development for the treatment of gout.
XRx-008 is being developed as a treatment of progressive kidney disease in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
XRx-101 is being developed to treat acute kidney injury as well as uric acid related health consequences associated with respiratory viruses including Coronavirus / COVID-19 infection.
At XORTX, we are dedicated to advancing treatments that improve the care and quality of life of patients suffering from life-threatening diseases.